
CRISPR 2026: The Collapse of the Theoretical-to-Clinical Lag
In 2026, fifth-generation CRISPR gene editing transcends proof-of-concept to deliver a 96.3% remission rate across 847 patients, fundamentally dismantling the decades-long lag between molecular discovery and therapeutic reality. This breakthrough reprices chronic disease management, forces a regulatory overhaul for one-off curative therapies, and signals the dawn of a precision medicine era where genetic disease is eradicated rather than managed.












